Figure 3

Combined HR to evaluate benefits of adding bevacizumab to chemotherapy versus chemotherapy alone in mCRC patients with or without primary tumor resection. (A) OS of bevacizumab plus chemotherapy versus chemotherapy alone in primary tumor resected patients (n = 847); (B) OS of bevacizumab plus chemotherapy versus chemotherapy alone in patients without resection of primary tumor (n = 424); (C) PFS of bevacizumab plus chemotherapy versus chemotherapy alone in primary tumor resected patients (n = 521); (D) PFS of bevacizumab plus chemotherapy versus chemotherapy alone in patients without resection of primary tumor (n = 252).